Acinetobacter baumannii is generally the most frequently isolated Acinetobacter species. Sequence analysis techniques allow reliable identification of Acinetobacter isolates at the species level. Forty-eight clinical isolates of Acinetobacter spp. were obtained from blood cultures at Tohoku University Hospital. These isolates were identified at the species level by partial sequencing of the RNA polymerase ␤-subunit (rpoB), 16S rRNA, and gyrB genes. Then further characterization was done by using the PCR for detection of OXA-type ␤-lactamase gene clusters, metallo-␤-lactamases, and carO genes. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing were also performed. The most frequent isolate was Acinetobacter soli (27.1%). Six of the 13 A. soli isolates were carbapenem nonsusceptible, and all of these isolates produced IMP-1. PFGE revealed that the 13 A. soli isolates were divided into 8 clusters. This study demonstrated that A. soli accounted for a high proportion of Acinetobacter isolates causing bacteremia at a Japanese tertiary hospital. Non-A. baumannii species were identified more frequently than A. baumannii and carbapenem-nonsusceptible isolates were found among the non-A. baumannii strains. These results emphasize the importance of performing epidemiological investigations of Acinetobacter species.
A cinetobacter species are strictly aerobic Gram-negative coccobacillary rods that are nonfermentive. During the last 20 years, Acinetobacter spp. have been reported to have caused pneumonia, sepsis, wound infection, and various opportunistic infections, and these bacteria have been emerging as a cause of nosocomial infections. Because Acinetobacter spp. are resistant to various antimicrobial agents, treatment of these infections can be challenging (1) .
A. baumannii generally represents the most clinically important and frequently isolated of the Acinetobacter spp. (2) . However, according to a recent report from Norway, Acinetobacter nosocomialis was the most frequent isolate from blood cultures (3) . Since the biochemical characteristics of different Acinetobacter spp. are almost identical to those of each other, accurate identification at the species level is difficult with routine laboratory methods. Recently, some molecular techniques have been reported for identifying isolates at the species level, such as sequencing the 16S rRNA gene, the gyrB gene, the recA gene, or the RNA polymerase ␤-subunit (rpoB) gene (4) (5) (6) (7) . These molecular methods recently led to progress in the accurate identification of Acinetobacter species.
There is a possibility of different clinical outcomes due to infection with different genospecies, since a difference in antibiotic susceptibility between A. baumannii and non-A. baumannii has been reported, and of differences in antibiotic resistance mechanisms among Acinetobacter spp. (8) (9) (10) . Accordingly, when Acinetobacter spp. are isolated from a patient with a severe infection, such as sepsis, it is very important to accurately identify the isolate at the species level. Clinically and epidemiologically valuable information is provided by investigating the prevalence, antimicrobial susceptibility patterns, and resistance mechanisms of the pathogens.
Therefore, this study was performed to clarify the species distributions, antibiotic susceptibility profiles, and carbapenem resistance mechanisms of 48 nonduplicate Acinetobacter spp. causing bacteremia at a Japanese tertiary hospital.
MATERIALS AND METHODS
Bacterial strains and identification. Forty-eight consecutive and nonduplicate clinical isolates of Acinetobacter spp. were obtained from blood cultures at Tohoku University Hospital (1,200 beds) between January 2007 and April 2012. These clinical isolates were obtained from inpatients who met at least two criteria for systemic inflammatory response syndrome (a temperature of Ͼ38°C or Ͻ36°C, a heart rate of Ͼ90 beats/min, a respiration rate of Ͼ20 breaths/min or a partial pressure of carbon dioxide [PaCO 2 ] of Ͻ32 mm Hg, and a white blood cell count of Ͼ12,000/ mm 3 or Ͻ4,000/mm 3 or Ͼ10% immature forms) (11) . The isolates were identified at the genus level by using the Vitek-2 system (Siemens Healthcare Diagnostics Japan, Tokyo, Japan).
Species identifications of the isolates were initiated by partial sequencing of the rpoB gene (zone 1) according to the method of Karah et al. (3, 4) . PCR products were purified with a QIAquick PCR purification kit (Qiagen, Hilden, Germany), followed by DNA sequencing using an ABI BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI3730xl analyzer (Applied Biosystems). BLASTn (see http://www.ddbj.nig.ac.jp/) was used for sequence analysis. A. soli was identified by partial sequencing of the rpoB gene (zone 2), plus sequencing of the gyrB and 16S rRNA genes, and by sequencing zone 1 of rpoB (4-7). The 16S rRNA gene sequences were analyzed by the EzTaxon-e server (see http://eztaxon-e.ezbiocloud.net/). Antimicrobial susceptibility testing. MICs were determined according to the methods and breakpoints defined by the Clinical and Laboratory Standards Institute (CLSI) (12) . The agar dilution method was used to obtain the MICs for the following antimicrobial agents: ampicillinsulbactam (Pfizer, New York City, NY, USA), piperacillin (Sigma-Aldrich), piperacillin-tazobactam (Sigma-Aldrich), cefotaxime (Sigma-Aldrich), ceftazidime (Sigma-Aldrich), cefepime (Bristol-Myers Squibb, Tokyo, Japan), imipenem (Banyu Pharmaceutical, Tokyo, Japan), meropenem (Dainippon Sumitomo Pharma, Osaka, Japan), gentamicin (SigmaAldrich), amikacin (Sigma-Aldrich), levofloxacin (Daiichi Sankyo), and colistin (Sigma-Aldrich). The range of concentrations tested was 0.06 to 256 g/ml, and the quality control strains were Escherichia coli ATCC 25922 and E. coli ATCC 35218.
Molecular characterization of ␤-lactamase genes. All isolates were further characterized by employing PCR for the detection of the following genes: OXA-51-like, OXA-23-like, OXA-24-like, OXA-58-like, OXA-143-like, OXA-245-like, ISAba1/bla OXA-58 -like complex, ISAba2/bla OXA-58 -like complex, ISAba3/bla OXA-58 -like complex, IS18/bla OXA-58 -like complex, metallo-␤-lactamase (MBL) genes (including IMP-1, IMP-2, VIM-1, VIM-2, SIM-1, and NDM-1), and the carO (outer membrane protein) gene (13) (14) (15) (16) (17) .
Sequencing of the OXA-type ␤-lactamase and MBL genes was performed according to the method of Pournaras et al. (18) . BLASTn was used for sequence analysis.
Molecular typing by pulsed-field gel electrophoresis and multilocus sequence typing analysis. The clonal relationships of A. soli isolates were determined by pulsed-field gel electrophoresis (PFGE) with the SmaI restriction enzyme (19) . Cluster analysis was done with GelCompar II v.3.0 (Applied Maths, Sint-Martens-Latem, Belgium) and the unweighted-pair group method using arithmetic averages (UPGMA). Strains were considered to belong to the same cluster if they showed Ն80% similarity with the PFGE profile (20) .
Using seven housekeeping genes (gltA, gyrB, gdhB, recA, cpn60, gpi, and rpoD), multilocus sequence typing (MLST) was performed for all A. baumannii isolates according to the method of Bartual et al. (21) . DNA sequence variations were analyzed by using an MLST database for A. baumannii (see http://pubmlst.org/abaumannii/). (3, 6 .3%), Acinetobacter genomic species "close to 13TU" (1, 2.1%), A. junii (1, 2.1%), and A. guillouiae (1, 2.1%). The 13 A. soli isolates showed 99 to 100% similarity to strain CCUG 59023 (GenBank accession number HQ148175) with respect to the sequences of zones 1 and 2 of the rpoB gene. These isolates also showed 99.5 to 100% similarity to A. soli strain B1
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T (GenBank accession number EU290155) with respect to the 16S rRNA gene sequence and Ն97.5% similarity to strain JCM 15062 (accession number; JQ411222) for the gyrB gene sequence.
Antimicrobial susceptibility. Antimicrobial nonsusceptibility rates are displayed in Table 1 . None of the isolates showed a reduced susceptibility to three or more of the antimicrobial agents tested. Of the Acinetobacter spp., only one strain of A. nosocomialis was resistant to both aminoglycosides and quinolones, while one strain of A. ursingii was resistant to aminoglycosides and carbapenems. In addition, 4 A. soli strains were resistant to carbapenems and quinolones.
Molecular characterization by PCR and sequencing. The distribution of carbapenem resistance genes among Acinetobacter spp. (imipenem-nonsusceptible isolates) is show in Table 2 . PCR amplification and sequencing revealed that A. soli and A. ursingii possessed bla IMP-1 and had no carO gene. Four A. soli strains and 1 A. ursingii strain possessed the bla OXA-58 -like gene, but it was not linked to ISAba1, ISAba2, ISAba3, or IS18. Carbapenem-susceptible non-A. baumannii species had no bla OXA-51 -like genes. Among isolates that were susceptible to imipenem, only one A. ursingii strain possessed the bla OXA-58 -like gene, but it was not linked to ISAba1, ISAba2, ISAba3, or IS18.
Molecular typing. PFGE indicated that the 13 A. soli isolates were divided into 8 clusters (Fig. 1) . In addition, the 12 A. nosocomialis isolates were divided into 12 clusters, the 9 A. baumannii isolates into 9 clusters, and the 8 A. ursingii isolates into 8 clusters. When characterized by MLST, the A. baumannii isolates were divided into sequence types 80, 86, 144, 161, 163, 175, 262, and 308.
DISCUSSION
Acinetobacter spp. can cause severe infections in hospitalized patients with compromised immune systems, including those who are dependent on medical devices. During the past few years, Acinetobacter spp. have emerged as a cause of nosocomial infection in Japan. However, there have been few reports about Acinetobacter from Japan, despite many reports from other countries. In general, the most frequent clinical isolate among Acinetobacter spp. has been reported to be A. baumannii (2) . Current molecular methods have revealed 27 valid species within the Acinetobacter genus (22) . In the present study, we used molecular techniques to investigate the frequency of Acinetobacter isolates causing bacteremia at a tertiary hospital in Japan. As with reports from other countries, this study showed that the clinical isolates of Acinetobacter spp. from blood cultures included a high percentage of non-A. baumannii species. The present study also revealed a high isolation rate for A. soli, although there have been few reports from elsewhere in the world about this microbe. A. soli was first reported by Kim et al. in 2008 (4) . In the present study, we identified A. soli by sequence analysis of the rpoB gene (zones 1 and 2) , the 16S rRNA gene, and the gyrB gene. According to the results of our genetic analyses, 13 isolates showed an extremely high similarity to A. soli (GenBank accession no. HQ148175, EU290155, and JQ411222), which strongly suggests that they were A. soli strains. The 13 A. soli strains isolated from blood cultures in the present study were divided into 8 clusters according to PFGE (Fig. 1) . Strains 10397 and 11584 (cluster A) were isolated from patients in the intensive care unit (ICU) but were isolated at different times, and there was no interaction between the two patients, so common hospital equipment and/or staff need to be considered when examining the potential relationship between the two cluster A strains isolated from the ICU.
For cluster B, the timing of isolation and the department involved differed among each strain. Thus, it was impossible to determine solely from PFGE analysis that any of the A. soli strains in clusters A or B was responsible for an outbreak.
In contrast, some of the A. soli strains isolated from patients in the intensive care unit harbored IMP-1 in the present study. Unlike the chromosomal bla OXA-51 -like genes, mobilization of the IMP metallo-␤-lactamase gene via plasmids may have resulted in the dissemination of IMP to non-A. baumannii species. For example, IMP-1 producing Acinetobacter spp. were first reported in 1998 among carbapenem-resistant strains carrying the bla IMP-1 gene in a Brazilian hospital, and by 2001, such resistance genes were detected among all carbapenem-resistant Acinetobacter spp. (23) . Previously, Yamamoto et al. reported on Acinetobacter isolates from certain areas of Japan and stated that IMP-19 was the predominant IMP in Acinetobacter spp. (24) . Conversely, in the present study, IMP-1 was predominant, and this difference between the two studies suggests that the predominant IMP type may differ from region to region and that a certain IMP type may easily disseminate via plasmids within a region. Furthermore, it has been reported that the prevalence of antimicrobial resistance varies widely among non-A. baumannii species (25) . This means that it is necessary to maintain surveillance for carbapenem-nonsusceptible non-A. baumannii species, including A. soli.
We found that the predominant Acinetobacter species isolated from blood cultures changed over time (data not shown). A. nosocomialis was most frequently isolated from blood cultures in 2007 and then gradually became less common, while A. soli was first isolated in 2008, and its isolation rate has since increased significantly. Epidemiological trends must continue to be tracked.
A. baumannii is generally reported to be the carbapenem-resistant Acinetobacter sp. that causes problematic infections in many patients (9, 10) . However, imipenem-nonsusceptible A. baumannii was not isolated in the present study. The reason for this may be that the number of isolates investigated was small. In addition, the prevalence of imipenem-nonsusceptible A. baumannii seems to be lower in Japan (26) than in other countries, and the A. baumannii isolates assessed in the present study were not clustered into clonal complex 92. Therefore, further research on a larger number of Acinetobacter strains isolated throughout Japan is needed.
We previously reported that imipenem-nonsusceptible A. baumannii in Japan possessed the OXA-51-like carbapenemase gene (26) , while this study showed that imipenem-nonsusceptible non-A. baumannii possesses metallo-␤-lactamase and the carO gene. Thus, we suggest the possibility of a different mechanism of nonsusceptibility to imipenem in A. baumannii and in non-A. baumannii species.
In conclusion, this is the first report describing a high rate of A. soli among Acinetobacter spp. causing bacteremia. In addition, the present results suggest that the distribution of Acinetobacter spp. may show regional differences. Clinical microbiology services need to supplement the identification of Acinetobacter genomic species by automated systems in order to accurately identify species for prevalence tracking and for the clinical treatment of patients; however, there are practically no reliable automated systems. Accordingly, our findings emphasize the importance of performing further epidemiological investigation of Acinetobacter species.
